CLRB

Cellectar Biosciences' stock price has experienced significant fluctuations in the past six months. On May 5, 2026, the share price was $3.18, a 55.98% decline from $7.22 on May 6, 2025. Positive 12-month follow-up data from the Phase 2b CLOVER WaM study and an oversubscribed financing of up to $140 million led to a positive market reaction on May 5, 2026. A subset of the CLOVER WaM clinical trial data was accepted for presentation at the American Society of Clinical Oncology Conference 2026 on April 21, 2026. The first patient was enrolled in a Phase 1b clinical trial for CLR 125 on April 14, 2026. Cellectar reported its financial results for the year ended 2025 on March 4, 2026, highlighting regulatory progress for iopofosine I 131 and the initiation of the CLR 125 study.